BMY241018P57500
- 3.25
- 0.000.00%
Bristol-Myers Squibb Newsroom
Jim Cramer on Bristol-Myers Squibb Company (BMY): 'I Think It's A Great Time To Consider Buying This One'
After eight weeks of selling off, the hedge fund bought back US stocks, achieving the fastest speed since 2021.
The US stock market is currently experiencing active buying and market growth, but the market's high valuation is a concerning issue that may trigger future adjustments.
The Zacks Analyst Blog Highlights Bristol-Myers Squibb, Arthur J. Gallagher, TC Energy and Bridger Aerospace
With 77% Institutional Ownership, Bristol-Myers Squibb Company (NYSE:BMY) Is a Favorite Amongst the Big Guns
Bristol-Myers Squibb: Hold Rating With Anticipated Revenue Outperformance Offset by Generic Competition Concerns
Bristol-Myers Squibb (BMY.US) Nivolumab combined with Ipilimumab therapy approved in China
On October 14, Bristol-Myers Squibb (BMY.US) announced that its 'Dual Immune Checkpoint Therapy' application for the combination of Nivolumab and Ipilimumab has been approved by the China National Medical Products Administration (NMPA).
Express News | Bristol-Myers Squibb: Opdivo and Yervoy dual immunotherapy new indications approved in China
Bristol Myers Squibb (BMY) Stock Falls Amid Market Uptick: What Investors Need to Know
Cancer-Focused Perspective Therapeutics Stock Trades Lower After Drug Study Report
Perspective Falls After Data for Radiopharmaceutical in Skin Cancer
Morgan Stanley Maintains Bristol-Myers Squibb(BMY.US) With Sell Rating, Maintains Target Price $37
Kyverna, Cabaletta Started at Buys by UBS on CAR T Therapy Potential
Correction to Old Drug Repurposed Article on Oct. 7 -- WSJ
BMY Buoyed by Recent Regulatory Updates: How to Play the Stock?
UBS Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Raises Target Price to $54
TD Cowen Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Raises Target Price to $59
Barclays Maintains Underweight on Bristol-Myers Squibb, Raises Price Target to $43
Reviva Pharmaceuticals Schizophrenia Drug Demonstrates Strong Efficacy On Heels Of Bristol Myers, FDA Approval: Analyst
Unveiling 11 Analyst Insights On Bristol-Myers Squibb
Bristol-Myers Squibb Is Maintained at Hold by TD Cowen